Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Neuro Oncol 2005 7(3):260-278; DOI:10.1215/S1152851704001188
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graner, M. W.
Right arrow Articles by Bigner, D. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Duke University Press

Tumor Biology

Chaperone proteins and brain tumors: Potential targets and possible therapeutics

Michael W. Graner2 and Darell D. Bigner

Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA

2 Address correspondence to Michael W. Graner, Duke University Medical Center, Department of Pathology, MSRB 173A, Durham, NC 27710, USA (michael.graner{at}duke.edu).

Abstract

Chaperone proteins are most notable for the proteo- and cyotoprotective capacities they afford during cellular stress. Under conditions of cellular normalcy, chaperones still play integral roles in the folding of nascent polypeptides into functional entities, in assisting in intracellular/intraorganellar transport, in assembly and maintenance of multi-subunit protein complexes, and in aiding and abetting the degradation of senescent proteins. Tumors frequently have relatively enhanced needs for chaperone number and activity because of the stresses of rapid proliferation, increased metabolism, and overall genetic instability. Thus, it may be possible to take advantage of this reliance that tumor cells have on chaperones by pharmacologic and biologic means. Certain chaperones are abundant in the brain, which implies important roles for them. While it is presumed that the requirements of brain tumors for chaperone proteins are similar to those of any other cell type, tumor or otherwise, very little inquiry has been directed at the possibility of using chaperone proteins as therapeutic targets or even as therapeutic agents against central nervous system malignancies. This review highlights some of the research on the functions of chaperone proteins, on what can be done to modify those functions, and on the physiological responses that tumors and organisms can have to chaperone-targeted or chaperone-based therapies. In particular, this review will also underscore areas of research where brain tumors have been part of the field, although in general those instances are few and far between. This relative dearth of research devoted to chaperone protein targets and therapeutics in brain tumors reveals much untrodden turf to explore for potential treatments of these dread fully refractive diseases.




This article has been cited by other articles:


Home page
J. Neurosci.Home page
M. W. Graner, R. I. Cumming, and D. D. Bigner
The Heat Shock Response and Chaperones/Heat Shock Proteins in Brain Tumors: Surface Expression, Release, and Possible Immune Consequences
J. Neurosci., October 17, 2007; 27(42): 11214 - 11227.
[Abstract] [Full Text] [PDF]




  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Copyright 2005 by Society for Neuro-Oncology